GeneDx reported Q3 revenue up 52% year‑over‑year, driven by exome and genome test growth, and announced a commercial build‑out targeting the general pediatrics market. The company plans to nearly double its sales force to drive exome/genome adoption as first‑tier tests for developmental delay and intellectual disability following updated AAP guidance. GeneDx’s results showed exome/genome revenue grew 65% and now comprises a growing share of total revenues; the firm also reaffirmed raised full‑year guidance and highlighted investments in R&D and commercial infrastructure. Management said geographic deployment of sales will follow patient demand and reimbursement patterns. Separately, GeneDx has articulated strategic market capture, clinician engagement and platform improvements to bring genomic testing into routine pediatric care, a move with implications for payer coverage and downstream diagnostic volumes.